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Abstract: Deepening our understanding of mammalian gut
microbiota has been greatly hampered by the lack of a facile,
real-time, and in vivo bacterial imaging method. To address
this unmet need in microbial visualization, we herein report the
development of a second near-infrared (NIR-II)-based method
for in vivo imaging of gut bacteria. Using d-propargylglycine
in gavage and then click reaction with an azide-containing
NIR-II dye, gut microbiota of a donor mouse was strongly
labeled with NIR-II fluorescence on their peptidoglycan. The
bacteria could be readily visualized in recipient mouse gut with
high spatial resolution and deep tissue penetration under NIR
irradiation. The NIR-II-based metabolic labeling strategy
reported herein, provides, to the best of our knowledge, the
first protocol for facile in vivo visualization of gut microbiota
within deep tissues, and offers an instrumental tool for
deciphering the complex biology of these gut “dark matters”.
Our understanding of the diverse physiological and patho-
logical roles of gut microbiota, considered by many as a long-
hidden organ, has been making strides in the last two decades.
By their inherent involvement in immune and metabolic
functions, these intestinal microbes were shown to have broad
and profound impacts on nearly every system of their
mammalian hosts.[1] However, advancing our knowledge of
these biological processes has been seriously obstructed by
the technical deficiencies in imaging and tracking intestinal
bacteria when real-time and in vivo biogeographical infor-
mation is required.[2] Needless to say, imaging is uncontested
in its ability to allow the study of highly complex and
heterogeneous biological systems like the gut microbiota.[3] A
competent visualization method can help researchers under-
stand gut microbiota in many aspects, such as microbe–
microbe and microbe–host interactions, temporal and spatial
organization of bacteria, and more of the bacterial commun-
ity on the macroscale.[4] The imaging protocol should be not
only biocompatible to the oxygen-sensitive gut microbes, but
also highly efficient to cover hundreds of different bacterial
species, many of which still cannot be cultured or genetically
engineered.[5] Furthermore, because the mammalian micro-
biota is always embedded in thick tissues, the method should
have excellent tissue penetration capability to realize in vivo
imaging.
Despite these difficulties and challenges, substantial
efforts have been made by both chemists and microbiologists
in developing imaging techniques for living gut microbiotas.
Current strategies can be classified into two categories. One is
based on the tracing of genetically engineered bacteria, and
the other involves the use of chemical probes tagged onto
bacterial surfaces for imaging analysis. Reporter genes used in
genetic engineering include fluorescent protein genes,[6]
bioluminescence genes (luciferase),[7] and acoustic response
genes.[8] The genetically modified bacteria can be tracked
longitudinally by different equipment, but each has its own
limitations. For example, luciferases and most fluorescent
proteins require oxygen for signal production or chromo-
phore maturation, while the hypoxic environment in the
intestine dramatically compromises their use in imaging gut
bacteria in vivo.[9] Moreover, in vivo bacterial imaging by
detecting bioluminescence often had unsatisfactory spatial
resolution.[10] Bacteria engineered with acoustic reporter
proteins, which could form hollow nanostructures inside
bacteria and respond to ultrasound detection, exhibited
improved spatial resolution and suitability to anaerobic
environment.[11] Notwithstanding these advantages, the use
of this method, like other genetic engineering strategies, is
limited to genetically modifiable bacteria, which currently
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account for only a very small proportion of intestinal bacteria.
Therefore, it is still impossible to image the whole gut
microbiota community using reporter genes. To overcome
these limitations, chemical labeling strategies have been
developed. One of these methods took advantage of the
binding capabilities and specificities of certain antibiotics.
Fluorophore-tagged antibiotics stained specific groups of gut
bacteria and showed promising imaging results on intestinal
tissue sections.[12] However, because of the bactericidal effects
of these probes, they could only be used in vitro.[13] Recently,
however, metabolic labeling strategies using bioorthogonal
chemical probes, including azidosugars and d-amino acid
(DAA)-based metabolic probes, have also been employed in
imaging gut microbes.[4b, 12, 14] After a click reaction with
alkyne-functionalized fluorophores, this method enabled
fluorescent tagging of bacteria and the subsequent imaging
of living bacteria in the gut, and the selection of different
labeling probes made the imaging of different bacterial
groups possible. Nonetheless, the low tissue penetration of
regular fluorescence signals excluded their use in in vivo
visualization. Recent progress in second NIR window (NIR-
II, 1000–1700 nm) fluorescence has demonstrated that NIR-II
imaging could achieve deep tissue penetration (up to 20 mm)
with superior temporal and spatial resolution,[15] and small
NIR-II fluorophores showed great biocompatibilities in
imaging.[16] Inspired by such advancements, we herein report
an in vivo imaging method for gut microbiota by integrating
the strategy of DAA-based metabolic labeling and NIR-II
fluorescence imaging.
NIR-II fluorescence has been widely utilized in tumor,
brain, stomach, and other deep tissue imaging.[17] However, its
use in gut microbial imaging has never been explored, which
can be partially attributed to the difficulties in efficient
fluorescence tagging of microbiotas. To label the gut micro-
biota with high coverage, efficiency, and cell compatibility, we
employed a DAA-based in vivo metabolic labeling strategy,
which we recently developed[18] and integrated it with click
reaction (Scheme shown in Figure 1 a) using an azide-
containing NIR-II dye (IR-FGN, Figure 1b). d-Alanine is
a conserved amino acid at the peptidoglycan (PGN) stem
peptide of bacteria, and d-amino acid (DAA) with modified
side chains, can be tolerated by the enzymes involved in PGN
synthesis and used as PGN-specific metabolic labeling probes.
Owing to its high specificity and coverage, the d-propargyl-
glycine (DPG, an alkyne-containing DAA, Figure 1b) probe
allowed ready labeling of intestinal microbes with the
bioorthogonal alkynyl group on their surfaces. Aqueous
solutions of DPG (2 X 200 mL, 1 mm) were given to C57BL/6
mice by gavage with an interval of 3 h. Their cecal microbes
were then collected, washed and clicked with the IR-FGN,
using a protocol that we previously optimized for bacterial
samples with minimum microbial cytotoxicity (Supporting
Information, Figure S1).[12] The NIR-II dye IR-FGN, the
maximum absorption and emission of which were at 745 and
1050 nm, respectively (Figure 1c), was chosen for its high
tissue penetration, water solubility, and excellent quantum
yield.[19] The resulting microbiota showed strong NIR-II
fluorescence signals after the click reaction (Figure 1d), in
Figure 1. a) Scheme of the NIR-II-based fluorescence imaging of gut microbiota. b) Chemical structures of the metabolic labeling probe d-
propargylglycine (DPG) and the NIR-II dye IR-FGN used in this study. c) The normalized absorption and emission spectra of the IR-FGN used in
this study. The spectra were measured with 5.0 mL of 10 mm IR-FGN DMSO solution dispersed in 500 mL of water. d) Imaging of DPG-labeled
microbiota before and after click reaction with IR-FGN under bright-field (BF) or NIR-II illumination (under 730 nm excitation, signals collected
with wavelength >1100 nm, exposure time: 100 ms).
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which the IR-FGN concentration was about 16 mm (Support-
ing Information, Figure S2). In a control group, l-propargyl-
glycine (LPG), which could not metabolically label bacte-
ria,[20] was used in mouse gavage. In contrast to DPG-labeled
microbiota, the LPG-labeled gut microbiota showed very low
level of fluorescence after click reaction (Supporting Infor-
mation, Figure S3), which might be resulted from non-specific
binding of the fluorophore to the bacteria. This indicated that
the NIR-II signals from DPG-labeled microbiota were from
the covalently modified PGN of the bacteria. Compared with
other chemical fluorescence-tagging methods for cells, such as
the protocol using reactive fluorophores to directly react with
amino groups on bacterial surfaces,[21] our metabolic labeling
strategy allowed precise labeling of PGN. In an attempt to
improve click reaction efficiency, a polyethylene glycol
(PEG)-modified NIR-II dye (structure shown in Figure S4
in the Supporting Information), which had the same fluoro-
phore, but with higher aqueous solubility,[19] was used in the
click reaction. It was, however, disappointing that the PEG-
modified dye somehow showed lower fluorescence intensity
compared with the dye without extra PEG modifications
(Supporting Information, Figure S5), perhaps because the
PEG sterically interfered with the reaction. Therefore, the
NIR-II dye without extra PEG was used in the following
experiment. Overall, our results established that mouse gut
microbiota can be facilely and efficiently labeled with the
NIR-II dye IR-FGN by in vivo DAA-based metabolic
labeling strategy followed by bioorthogonal click reactions.
Following giving the NIR-II-labeled microbiota to recip-
ient mouse by gavage, a series of in vivo imaging was carried
out for visualizing gut microbiota, using a 730 nm laser as the
excitation source and an InGaAs CCD as the signal collector.
Specific pathogen-free (SPF) BALB/c nude mice were first
used as recipients in order to eliminate the reflection of
mouse fur. Because of the low autofluorescence and photon
scattering in the> 1000 nm window of NIR-II fluorescence,[22]
the resulting high spatial resolution enabled vivid and clear
observation of the biogeography of gut microbes inside mouse
intestines through intact abdominal skin. Images were taken
at different time points to visualize the longitudinal distribu-
tions of the microbiota. Three hours after gavage, the bacteria
mostly showed in the duodenum, but by 5 h, the signals were
concentrated in different sections of the small intestines. The
most dramatic images were observed at 8 h after gavage,
where 6–7 segments of the small intestines and possibly cecum
could be clearly observed. By 11 h, due to the decay of the
PGN labeling, the bacterial fluorescence was decreased and
mainly localized in the cecum and colon (Figure 2 a). The
digestive tract of the mouse, together with some of the other
major organs, was then dissected and imaged. Along the small
intestine, the fluorescence signals mostly stayed in distal
jejunum and ileum, but not in proximal jejunum, probably
because of the fast emptying of the latter. Besides the
intestines, the signals were also found in liver and spleen
(Supporting Information, Figure S6). This could be explained
by the degraded bacterial PGN, which had been labeled by
the IR-FGN, entering the circulation through the hepatic
portal system. Taken together, these data showed that the
NIR-II imaging strategy, facilitated by the use of PGN
metabolic labeling, allowed clear observation of the biogeog-
raphy of the gut microbiota in the extensively used SPF
mouse model. Because the labeled microbiota was given to
the recipient mice by gavage, some of the bacteria might not
survive during the process due to the stomach acid and bile
acid encountered by the microbes. To determine to which
extent the observed fluorescence signals were resulted from
living bacteria, recipient mouse was gavaged with NIR-II
labeled microbioa that had been killed by ethanol, and
imaged. The dead microbiota presented dispersed fluores-
cence signals in the gut, without any clear outlines of the
intestinal track (Supporting Information, Figure S7). The
dramatically different fluorescence signals presented by the
dead microbiota suggested that the vivid imaging of the
transplanted bacteria shown in Figure 2 were mainly from
living microbes.
Besides SPF mouse, germ-free (GF) mouse has been
widely employed in microbiota research to validate the
causality after being given specific bacteria or microbiota of
interest by gavage.[23] Therefore, the ability to track trans-
planted bacteria in the GF mouse is important to researchers.
By administering NIR-II-labeled microbiota in gavage to
a group of GF C57BL/6 mice, we were able to visualize the
localization of the transplanted bacteria. Mouse abdomen was
depilated before imaging to reduce fur reflection. Compared
with the SPF mouse, stronger fluorescence in more intestinal
areas was observed by 3 h, and during the period of 5–8 h, the
microbiota seemed to stay longer in the gut, and even the gas
in the small intestines, which was often seen in the gut of GF
mice after they were exposed to bacteria, could be clearly
observed (Figure 2b, arrows). By 11 h, the bacteria reached
the cecum, which was much larger than that of the SPF mouse
and could be visualized with unprecedented resolution,
together with the pellets stored in the gut (Figure 2b). The
labeled gut microbiota showed stronger signals in GF mouse,
Figure 2. NIR-II-based fluorescence imaging of labeled gut microbiota
at different time points following transplantation in SPF (a) and GF
mouse (b) (under 730 nm excitation, signals collected with wavelength
>1100 nm, exposure time: 100 ms). Representative images from at
least three independent experiments were shown.
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when compared to SPF mouse, most likely because of the
larger cecal volume and the absence of competition from the
original microbiota in SPF animals.
To extend the use of this chemical strategy to a broader
scope of microbiology, we went on to test its feasibility in
imaging specific bacterial species in the gut. Two commensal
and a pathogenic bacteria were NIR-II-labeled in vitro and
given to recipient mice by gavage, respectively. A similar
labeling strategy was adopted whereby DPG was supple-
mented to the bacterial culture medium, and IR-FGN was
tagged onto the bacterial surface by click chemistry after-
wards. As shown in Figure 3, the three bacterial species (two
Gram-negative and one Gram-positive species) could all be
NIR-II-labeled in vitro (LPG labeled control shown in
Figure S8 in the Supporting Information) and clearly visual-
ized in vivo after intragastric administration to mice. Cur-
rently, the most used method for in vivo bacterial imaging is
based on bioluminescence.[10] This requires genetic engineer-
ing of the target bacteria and the presence of oxygen to
produce signals, both of which meet great challenges in
imaging gut bacteria in vivo. In contrast, our imaging strategy
is immune to these problems, and the spatial resolution is
much higher compared with that of bioluminescence-based
imaging in the gut.[7]
Taking advantage of our in vivo microbiota imaging
strategy, which enabled facile, real-time assessment of the gut
microbial movement, we went on to approach a long-asked
question regarding gastrointestinal (GI) motility and its effect
on the movement and localization of gut microbiota. Because
of its involvement in many diseases, like irritable bowel
syndrome, constipation, or small bowel bacterial overgrowth
syndrome, the relationship between GI peristalsis and gut
microbiota has been extensively studied in neurogastroenter-
ology.[24] Previous investigations of these reciprocal interac-
tions used methods like measuring ink propulsion rates or
defecating time by collecting fecal pellet output,[25] which
were often invasive or indirect. Here, by using our NIR-II-
based imaging method, we were able to directly compare
microbiota distributions in different groups of mice treated
with loperamide or domperidone, which could either slow
down or accelerate GI movement. The drugs were given to
mice by gavage 30 min before receiving the labeled micro-
biotas. As shown in Figure 4, gut microbes showed distinct
distribution patterns in the two groups. In the domperidone-
treated mouse, the microbiota reached cecum in < 8 h after
Figure 3. NIR-II-based fluorescence imaging of labeled bacterial spe-
cies following transplantation in SPF mouse. a) NIR-II imaging showed
that three bacterial species, Escherichia coli, Bacillus subtilis, and
Salmonella enterica serovar Typhimurium, metabolically labeled by DPG
in vitro, all showed strong fluorescence after click with IR-FGN. b–
d) In vivo NIR-II imaging of the labeled bacteria 5 h after the gavage of
corresponding bacterial species (under 730 nm excitation, signals
collected with wavelength >1100 nm, exposure time: 100 ms). Repre-
sentative images from at least three independent experiments were
shown.
Figure 4. NIR-II fluorescence imaging showed that GI peristalsis
dramatically affected the biogeography of gut microbiota. Visualization
of the NIR-II-labeled microbiota in the gut of mice treated with
domperidone (a) or loperamide (b). Ex vivo NIR-II imaging of the
administered microbiotas in the intestines of domperidone- (c) or
loperamide-treated (d) mice (under 730 nm excitation, signals col-
lected with wavelength >1100 nm, exposure time: 100 ms). Represen-
tative images from at least three independent experiments were
shown.
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gavage (Figure 4a), while in the loperamide-treated mouse,
most signals remained in the small intestines, especially in
ileum (Figure 4b). The movement of microbiota caused by GI
peristalsis was also captured on video in the domperidone-
treated mouse, the fluorescence signals of which could be
clearly observed in real time (Supplementary Materials). To
examine the affected bacterial biodistributions more closely,
in another two groups of mice, the treated animals were
sacrificed at each time point, and their digestive tracts were
dissected and imaged directly. Microbiota in the domper-
idone-treated mouse arrived at ileum by 3 h after gavage
(arrow, Figure 4c), but most bacteria had not even left the
stomach in the loperamide group (arrow, Figure 4d). By 9 h,
the bacteria either reached the large intestines or had already
been defecated in the domperidone-treated mouse (arrow,
Figure 4c), while most microbiota was still in the small
intestines in the loperamide group (arrow, Figure 4d). Taken
together, these data suggested that the biogeography of gut
microbiota could be greatly impacted by GI movements and
that the imaging strategy proposed here could assist in studies
where GI and microbiota movements were of interest.
In summary, we have established an in vivo imaging
method to fulfill the unmet need for gut microbiota visual-
ization by integrating the strategy of DAA-based metabolic
labeling and NIR-II fluorescence imaging. DAA-based met-
abolic labeling enables facile and precise labeling of both
microbiotas and individual bacterial species, some of which
may not be cultured or genetically engineered. The enhanced
imaging depth and high spatial resolution resulted from the
NIR-II fluorescence, allows real-time and vivid observation of
the bacteria embedded in deep tissues. The applicability of
this technique was also demonstrated in the study of GI
motility-induced gut microbiota biogeography changes. Fur-
ther development of this method to allow longer observation
window will enable more microbiota analyses such as com-
petition experiment between different bacterial groups for
example, which will greatly increase the power of this
methodology. We envision that this new imaging strategy
will be versatile and instrumental to a variety of microbiology
studies and pave a new way for a deeper understanding of gut
microbiota.
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